Concepts (203)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Herpesvirus 4, Human | 4 | 2015 | 198 | 0.850 |
Why?
|
| Infectious Mononucleosis | 3 | 2015 | 34 | 0.840 |
Why?
|
| HIV-1 | 11 | 2020 | 706 | 0.800 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2015 | 673 | 0.640 |
Why?
|
| Severe Acute Respiratory Syndrome | 5 | 2006 | 23 | 0.530 |
Why?
|
| HIV Infections | 8 | 2020 | 955 | 0.500 |
Why?
|
| Antibodies, Viral | 5 | 2021 | 325 | 0.410 |
Why?
|
| AIDS Vaccines | 2 | 2011 | 72 | 0.360 |
Why?
|
| Transcriptome | 1 | 2015 | 398 | 0.360 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2011 | 94 | 0.320 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 152 | 0.310 |
Why?
|
| Antigens, CD | 1 | 2010 | 342 | 0.300 |
Why?
|
| Fowlpox virus | 1 | 2008 | 4 | 0.290 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2010 | 281 | 0.290 |
Why?
|
| Viral Envelope Proteins | 4 | 2005 | 101 | 0.290 |
Why?
|
| Spike Glycoprotein, Coronavirus | 5 | 2021 | 114 | 0.250 |
Why?
|
| Antibodies, Monoclonal | 3 | 2006 | 875 | 0.240 |
Why?
|
| Membrane Glycoproteins | 4 | 2005 | 662 | 0.240 |
Why?
|
| Monkey Diseases | 1 | 2005 | 7 | 0.230 |
Why?
|
| Callithrix | 1 | 2005 | 21 | 0.230 |
Why?
|
| Immunization, Passive | 1 | 2005 | 96 | 0.220 |
Why?
|
| Anti-Retroviral Agents | 2 | 2019 | 76 | 0.220 |
Why?
|
| Immunity, Innate | 2 | 2021 | 819 | 0.210 |
Why?
|
| Genetic Variation | 2 | 2019 | 393 | 0.210 |
Why?
|
| Cytokines | 3 | 2021 | 951 | 0.200 |
Why?
|
| HIV | 2 | 2019 | 67 | 0.190 |
Why?
|
| Simian Immunodeficiency Virus | 3 | 2012 | 84 | 0.190 |
Why?
|
| Pneumonia | 1 | 2005 | 291 | 0.180 |
Why?
|
| Neutralization Tests | 4 | 2012 | 125 | 0.180 |
Why?
|
| Cell Nucleus | 1 | 2005 | 630 | 0.170 |
Why?
|
| Killer Cells, Natural | 2 | 2020 | 219 | 0.160 |
Why?
|
| Herpesvirus 1, Human | 1 | 2021 | 83 | 0.160 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2020 | 10 | 0.160 |
Why?
|
| Cell Line | 9 | 2021 | 2021 | 0.150 |
Why?
|
| Antibodies, Neutralizing | 1 | 2021 | 217 | 0.150 |
Why?
|
| Virus Latency | 1 | 2019 | 31 | 0.150 |
Why?
|
| Virus Replication | 6 | 2011 | 323 | 0.150 |
Why?
|
| Lymphocytes | 1 | 2020 | 204 | 0.150 |
Why?
|
| B-Lymphocytes | 2 | 2014 | 563 | 0.140 |
Why?
|
| Liver Transplantation | 1 | 2020 | 219 | 0.140 |
Why?
|
| RNA, Viral | 3 | 2011 | 266 | 0.140 |
Why?
|
| Adolescent | 6 | 2019 | 6293 | 0.130 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2019 | 637 | 0.130 |
Why?
|
| Sequence Analysis, DNA | 4 | 2019 | 414 | 0.120 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 3 | 2019 | 26 | 0.120 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2015 | 16 | 0.120 |
Why?
|
| Humans | 24 | 2021 | 64958 | 0.120 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2016 | 29 | 0.120 |
Why?
|
| Acute Disease | 2 | 2015 | 663 | 0.120 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2015 | 26 | 0.120 |
Why?
|
| Viral Matrix Proteins | 2 | 2014 | 50 | 0.120 |
Why?
|
| Ebolavirus | 1 | 2016 | 39 | 0.110 |
Why?
|
| Uveitis | 1 | 2016 | 34 | 0.110 |
Why?
|
| Cells, Cultured | 3 | 2010 | 2188 | 0.110 |
Why?
|
| Oropharynx | 1 | 2014 | 12 | 0.100 |
Why?
|
| Molecular Sequence Data | 5 | 2014 | 1979 | 0.090 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2014 | 104 | 0.090 |
Why?
|
| Vaccines, Synthetic | 2 | 2011 | 80 | 0.090 |
Why?
|
| Lung | 3 | 2006 | 962 | 0.090 |
Why?
|
| Up-Regulation | 2 | 2010 | 373 | 0.090 |
Why?
|
| Dengue | 1 | 2011 | 96 | 0.080 |
Why?
|
| Viremia | 1 | 2011 | 46 | 0.080 |
Why?
|
| DNA, Complementary | 1 | 2011 | 165 | 0.080 |
Why?
|
| Coinfection | 1 | 2011 | 58 | 0.080 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2010 | 62 | 0.080 |
Why?
|
| Peptidyl-Dipeptidase A | 3 | 2004 | 45 | 0.080 |
Why?
|
| Poxviridae | 1 | 2009 | 5 | 0.080 |
Why?
|
| Young Adult | 4 | 2019 | 4795 | 0.080 |
Why?
|
| Animals | 10 | 2021 | 21292 | 0.070 |
Why?
|
| CD4-CD8 Ratio | 1 | 2008 | 16 | 0.070 |
Why?
|
| Vaccinia | 1 | 2008 | 29 | 0.070 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2008 | 92 | 0.070 |
Why?
|
| Gene Products, gag | 1 | 2008 | 66 | 0.070 |
Why?
|
| Ferritins | 1 | 2008 | 30 | 0.070 |
Why?
|
| Epitope Mapping | 2 | 2005 | 52 | 0.070 |
Why?
|
| Carboxypeptidases | 2 | 2004 | 9 | 0.070 |
Why?
|
| Virulence Factors | 1 | 2008 | 85 | 0.070 |
Why?
|
| Interferon-alpha | 1 | 2008 | 101 | 0.070 |
Why?
|
| Female | 6 | 2019 | 33929 | 0.070 |
Why?
|
| CD4 Antigens | 1 | 2008 | 149 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2015 | 1551 | 0.070 |
Why?
|
| Protein Binding | 3 | 2012 | 1639 | 0.070 |
Why?
|
| HIV Antibodies | 1 | 2008 | 146 | 0.070 |
Why?
|
| Amino Acid Sequence | 3 | 2005 | 1589 | 0.070 |
Why?
|
| Gene Expression | 1 | 2010 | 852 | 0.060 |
Why?
|
| Flow Cytometry | 1 | 2008 | 662 | 0.060 |
Why?
|
| Male | 5 | 2019 | 30957 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 2008 | 574 | 0.060 |
Why?
|
| Inflammation | 2 | 2020 | 1186 | 0.060 |
Why?
|
| Mutation | 2 | 2005 | 2657 | 0.060 |
Why?
|
| Viral Structural Proteins | 1 | 2005 | 17 | 0.060 |
Why?
|
| DNA, Viral | 2 | 2019 | 231 | 0.060 |
Why?
|
| HIV Long-Term Survivors | 1 | 2005 | 8 | 0.060 |
Why?
|
| Gene Products, vif | 1 | 2005 | 9 | 0.060 |
Why?
|
| Antibody Specificity | 1 | 2005 | 102 | 0.060 |
Why?
|
| vif Gene Products, Human Immunodeficiency Virus | 1 | 2005 | 13 | 0.060 |
Why?
|
| Mice, Transgenic | 2 | 2008 | 1287 | 0.060 |
Why?
|
| Dendritic Cells | 1 | 2008 | 531 | 0.060 |
Why?
|
| Tissue Distribution | 1 | 2005 | 293 | 0.050 |
Why?
|
| Amino Acid Motifs | 1 | 2005 | 156 | 0.050 |
Why?
|
| Leukemia Virus, Murine | 1 | 2004 | 29 | 0.050 |
Why?
|
| Lymph Nodes | 1 | 2005 | 231 | 0.050 |
Why?
|
| Endopeptidases | 1 | 2004 | 67 | 0.050 |
Why?
|
| Adult | 5 | 2015 | 17314 | 0.050 |
Why?
|
| HIV Long Terminal Repeat | 1 | 2003 | 11 | 0.050 |
Why?
|
| Genes, nef | 1 | 2003 | 5 | 0.050 |
Why?
|
| Hepatocytes | 1 | 2005 | 222 | 0.050 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 1005 | 0.050 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 2003 | 25 | 0.050 |
Why?
|
| Epitopes | 1 | 2005 | 291 | 0.050 |
Why?
|
| Viral Load | 3 | 2011 | 230 | 0.050 |
Why?
|
| Heart | 1 | 2005 | 297 | 0.050 |
Why?
|
| Myocardium | 1 | 2005 | 301 | 0.050 |
Why?
|
| Mice | 4 | 2021 | 11088 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 1 | 2005 | 869 | 0.050 |
Why?
|
| Immunologic Memory | 2 | 2020 | 281 | 0.050 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2003 | 179 | 0.050 |
Why?
|
| Cell Fusion | 1 | 2021 | 39 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2008 | 3305 | 0.040 |
Why?
|
| Phylogeny | 2 | 2014 | 387 | 0.040 |
Why?
|
| Vaccines, Virus-Like Particle | 1 | 2021 | 16 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2003 | 687 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2006 | 2281 | 0.040 |
Why?
|
| Viral Vaccines | 1 | 2021 | 56 | 0.040 |
Why?
|
| Candidiasis, Invasive | 1 | 2020 | 9 | 0.040 |
Why?
|
| Candida | 1 | 2020 | 37 | 0.040 |
Why?
|
| Monocytes | 1 | 2002 | 361 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 110 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2020 | 125 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2020 | 206 | 0.040 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2019 | 4 | 0.040 |
Why?
|
| Wnt Signaling Pathway | 1 | 2020 | 86 | 0.040 |
Why?
|
| In Vitro Techniques | 1 | 2020 | 491 | 0.040 |
Why?
|
| Immunoglobulin G | 2 | 2012 | 464 | 0.030 |
Why?
|
| Homeostasis | 1 | 2020 | 377 | 0.030 |
Why?
|
| Child | 4 | 2011 | 4606 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2020 | 420 | 0.030 |
Why?
|
| Critical Care | 1 | 2020 | 400 | 0.030 |
Why?
|
| Liberia | 1 | 2016 | 11 | 0.030 |
Why?
|
| Vero Cells | 2 | 2005 | 81 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2021 | 917 | 0.030 |
Why?
|
| Transfection | 2 | 2008 | 701 | 0.030 |
Why?
|
| Receptors, Virus | 2 | 2004 | 73 | 0.030 |
Why?
|
| Jurkat Cells | 2 | 2003 | 109 | 0.030 |
Why?
|
| Time Factors | 2 | 2014 | 3758 | 0.020 |
Why?
|
| Tomography, Optical Coherence | 1 | 2016 | 235 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2014 | 261 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 1629 | 0.020 |
Why?
|
| Macaca | 1 | 2012 | 30 | 0.020 |
Why?
|
| Virology | 1 | 2012 | 13 | 0.020 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2012 | 29 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2011 | 2052 | 0.020 |
Why?
|
| Receptors, IgG | 1 | 2012 | 41 | 0.020 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2012 | 130 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 449 | 0.020 |
Why?
|
| Cross Reactions | 1 | 2011 | 139 | 0.020 |
Why?
|
| CCR5 Receptor Antagonists | 1 | 2011 | 17 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2021 | 3143 | 0.020 |
Why?
|
| Piperazines | 1 | 2011 | 86 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2011 | 206 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2011 | 145 | 0.020 |
Why?
|
| Genome, Viral | 1 | 2011 | 144 | 0.020 |
Why?
|
| Drug Resistance, Viral | 1 | 2011 | 160 | 0.020 |
Why?
|
| Immunization | 1 | 2009 | 135 | 0.020 |
Why?
|
| Vaccination | 1 | 2011 | 375 | 0.020 |
Why?
|
| Hypergammaglobulinemia | 1 | 2008 | 2 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2008 | 146 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 1692 | 0.020 |
Why?
|
| Genotype | 1 | 2009 | 673 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2007 | 138 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2011 | 1416 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2019 | 6844 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2008 | 434 | 0.020 |
Why?
|
| Infant | 1 | 2011 | 1683 | 0.020 |
Why?
|
| Mesocricetus | 1 | 2006 | 92 | 0.010 |
Why?
|
| Kidney | 1 | 2008 | 450 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2008 | 752 | 0.010 |
Why?
|
| Nucleocapsid Proteins | 1 | 2005 | 34 | 0.010 |
Why?
|
| Cricetinae | 1 | 2006 | 362 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2004 | 111 | 0.010 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2006 | 144 | 0.010 |
Why?
|
| U937 Cells | 1 | 2003 | 10 | 0.010 |
Why?
|
| Giant Cells | 1 | 2003 | 16 | 0.010 |
Why?
|
| Virion | 1 | 2004 | 122 | 0.010 |
Why?
|
| Gene Products, nef | 1 | 2003 | 13 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2003 | 193 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2006 | 271 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2007 | 1036 | 0.010 |
Why?
|
| Solubility | 1 | 2003 | 192 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2009 | 2614 | 0.010 |
Why?
|
| Antibodies | 1 | 2003 | 187 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2003 | 129 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2003 | 247 | 0.010 |
Why?
|
| Macrophages | 1 | 2008 | 1035 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2003 | 324 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2002 | 104 | 0.010 |
Why?
|
| Alleles | 1 | 2003 | 453 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2003 | 676 | 0.010 |
Why?
|
| Base Sequence | 1 | 2003 | 1329 | 0.010 |
Why?
|
| Rats | 1 | 2004 | 1989 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2011 | 5776 | 0.010 |
Why?
|
| Disease Progression | 1 | 2003 | 1214 | 0.010 |
Why?
|
| Middle Aged | 2 | 2008 | 18210 | 0.010 |
Why?
|